Multiple Manufacturers

BORTEZOMIB

Manufacturer:

Multiple Manufacturers

Bortezomib HCPCS:

J9041

HCPCS Code Descriptor:

Injection, bortezomib, 0.1 mg

Category:

J Code

Bortezomib NDCs:

63020-0049-01, 10019-0991-01, 71288-0118-10, 25021-0244-10, 55150-0337-01, 00143-9098-01, 70710-1411-01, 00409-1700-01, 70860-0225-10, 72205-0183-01, 68001-0534-36, 43598-0426-60, 68001-0541-36, 60505-6050-04, 63323-0821-10, 50742-0484-01, 68001-0540-36

Primary Type:

Oncology

Generic/Specialty Status:

Multi-Source

Package Type:

Vial

Route of Administration:

Injection

Bortezomib CPT Codes:

Potential CPT administration codes for Bortezomib can be found at the following link.

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

50742-0484-01, 72205-0183-01, 70860-0225-10, 70710-1411-01

About Bortezomib:

BORTEZOMIB is a medication manufactured by multiple manufacturers and aligned to the J Code: J9041. BORTEZOMIB is administered via the injection route of administration.

Bortezomib is an anti-cancer drug which inhibits rapid cell growth. This drug is administered by a doctor or a healthcare professional via injection into a vein. Bortezomib is a generic drug that is produced by multiple manufacturers including Fresenius Kabi, Hospira, Bluepoint Laboratories, Baxter, and others. Fresenius Kabi (J9048) and Hospira (J9049) each have their own unique HCPCS for Bortezomib distinct from the generic HCPCS code (J9041).

ACCESS PRICING AND MORE BY REGISTERING

J9041 Added Date:

January 1, 2005

J9041 Effective Date:

January 1, 2023

J9041 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Bortezomib billing and coding information.
Bortezomib patient assistance information can be found through Takeda Patient Support at the URL: https://www.velcade.com/support-from-takeda/
BORTEZOMIB prescribing information can be found at the link below:
Information regarding BORTEZOMIB’s side effects can be found at MedlinePlus